Form 4: Evoke Pharma Director Malcolm R. Hill Reports Stock Option Grant

Director Malcolm R. Hill reports the acquisition of stock options in Evoke Pharma, Inc.

Summary

• Malcolm R. Hill, a director of Evoke Pharma Inc, filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on May 22, 2024.
• Hill acquired stock options for 14,625 shares of common stock at an exercise price of $0.451.
• These options vest one year from the grant date, contingent upon continued service to the issuer.
• Following the transaction, Hill directly owns options for 14,625 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of stock option grants to a company director. It doesn't inherently indicate positive or negative performance.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates changes in the beneficial ownership of securities by a director of Evoke Pharma.

Stakeholder Impact

• The granting of stock options to a director can align their interests with shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates

Keywords

Form 4, Evoke Pharma, Stock Options, Director, Beneficial Ownership, EVOK, SEC Filing